We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-14.52%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$104M
AUM Growth
-$29.7M
Cap. Flow
-$5.31M
Cap. Flow %
-5.12%
Top 10 Hldgs %
92.65%
Holding
13
New
3
Increased
2
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
ACET icon
Adicet Bio
ACET
+$4.24M
2
BCYC
Bicycle Therapeutics
BCYC
+$3.54M
3
IMTX icon
Immatics
IMTX
+$2.25M
4
RPTX
Repare Therapeutics
RPTX
+$1.15M
5
ARVN icon
Arvinas
ARVN
+$733K

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$6.76M
2
MRUS
Merus
MRUS
+$5.18M
3
KYMR icon
Kymera Therapeutics
KYMR
+$2.08M
4
STRO icon
Sutro Biopharma
STRO
+$1.59M
5
SLN
Silence Therapeutics
SLN
+$1.57M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$12.4B
$23.6M 22.76%
908,474
– –
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$12.4M 11.91%
114,600
-67,551
-37% -$6.76M
ARVN icon
3
Arvinas
ARVN
$572M
$11.4M 11%
428,766
+23,000
+6% +$733K
RGNX icon
4
Regenxbio
RGNX
$708M
$10.6M 10.22%
906,248
– –
KYMR icon
5
Kymera Therapeutics
KYMR
$8.94B
$9.81M 9.46%
328,743
-60,000
-15% -$2.08M
SLN
6
Silence Therapeutics
SLN
$564M
$9.5M 9.16%
500,214
-74,000
-13% -$1.57M
MRUS
7
DELISTED
Merus
MRUS
$8.76M 8.45%
148,109
-107,000
-42% -$5.18M
DTIL icon
8
Precision BioSciences
DTIL
$207M
$3.71M 3.58%
381,803
-3,637
-0.9% -$42.8K
BCYC
9
Bicycle Therapeutics
BCYC
$292M
$3.17M 3.06%
+156,692
New +$3.54M
RPTX
10
DELISTED
Repare Therapeutics
RPTX
$3.16M 3.04%
956,932
+323,661
+51% +$1.15M
ACET icon
11
Adicet Bio
ACET
$74.7M
$3.06M 2.95%
+158,200
New +$4.24M
IMTX icon
12
Immatics
IMTX
$1.32B
$2.32M 2.24%
+200,000
New +$2.25M
STRO icon
13
Sutro Biopharma
STRO
$421M
$2.23M 2.15%
76,250
-40,297
-35% -$1.59M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Aquilo Capital Management held 13 positions worth $104M, down 22% from $133M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Aquilo Capital Management withdrew a net $5.31M in Q2 2024, reducing 6 holdings. Its largest reduction was Blueprint Medicines, cutting an estimated $6.76M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Aquilo Capital Management opened a new position in Adicet Bio worth $3.06M.

  • Aquilo Capital Management's largest Q2 2024 buy was Adicet Bio: 158,200 shares worth $3.06M.
  • Aquilo Capital Management added most to Repare Therapeutics in Q2 2024, an estimated $1.15M increase.
  • Aquilo Capital Management's biggest Q2 2024 reduction was Blueprint Medicines, cutting an estimated $6.76M.
  • Aquilo Capital Management's ten largest holdings make up 93% of its $104M portfolio in Q2 2024.
  • Aquilo Capital Management opened 3 new positions and closed 0 in Q2 2024.
  • Aquilo Capital Management's portfolio value fell 22% quarter-over-quarter to $104M.

Based on Aquilo Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.